Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

ClinicalTrials.gov ID: NCT06018428

Public ClinicalTrials.gov record NCT06018428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.

Study identification

NCT ID
NCT06018428
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Q32 Bio Inc.
Industry
Enrollment
75 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 12, 2023 (Actual)
Primary completion
Jun 2026 (Estimated)
Completion
Sep 2026 (Estimated)
Last update posted
May 8, 2026

2023 – 2026

United States locations

U.S. sites
28
U.S. states
16
U.S. cities
27
Facility City State ZIP Site status
Scottsdale, Arizona Scottsdale Arizona 85255 —
Fayetteville, Arkansas Fayetteville Arkansas 72703 —
Hot Springs, Arkansas Hot Springs Arkansas 71913 —
Encinitas, California Encinitas California 92024 —
Fountain Valley, California Fountain Valley California 92708 —
Lomita, California Lomita California 90717 —
New Haven, Connecticut New Haven Connecticut 06519 —
Miami, Florida Miami Florida 33173 —
Tampa, Florida Tampa Florida 33613 —
Clarksville, Indiana Clarksville Indiana 47129 —
Bowling Green, Kentucky Bowling Green Kentucky 42104 —
Burlington, Massachusetts Burlington Massachusetts 01805 —
Troy, Michigan Troy Michigan 48084 —
Warren, Michigan Warren Michigan 48192 —
New York, New York New York New York 10012 —
New York, New York New York New York 10023 —
Wilmington, North Carolina Wilmington North Carolina 28405 —
Bexley, Ohio Bexley Ohio 43209 —
Clinical Trials Canton Ohio 44718 —
Mason, Ohio Mason Ohio 45040 —
Mayfield Heights, Ohio Mayfield Heights Ohio 44124 —
Portland, Oregon Portland Oregon 97225 —
Austin, Texas Austin Texas 78759 —
Frisco, Texas Frisco Texas 75034 —
Houston, Texas Houston Texas 77056 —
San Antonio, Texas San Antonio Texas 78213 —
Jordan, Utah Jordan Utah 84095 —
Spokane, Washington Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06018428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 8, 2026 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06018428 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →